The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes. [Review] (Record no. 11187)

MARC details
000 -LEADER
fixed length control field 02373nam a22003617a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 190823s20192019 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1738-5520
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.4070/kcj.2019.0185 [doi]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 49.e104 [pii]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code PMC6675700 [pmc]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 31347321
245 ## - TITLE STATEMENT
Title The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes. [Review]
251 ## - Source
Source Sunhwangi. 49(8):645-656, 2019 Aug.
252 ## - Abbreviated Source
Abbreviated source Korean circ. j.. 49(8):645-656, 2019 Aug.
253 ## - Journal Name
Journal name Korean circulation journal
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2019
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2020
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status ppublish
266 ## - Date added to catalog
Date added to catalog 2019-08-23
520 ## - SUMMARY, ETC.
Abstract Copyright (c) 2019. The Korean Society of Cardiology.
520 ## - SUMMARY, ETC.
Abstract The number of patients undergoing percutaneous coronary intervention (PCI) who mandate additional oral anticoagulant therapy has been increasing. Dual antiplatelet therapy (DAPT) is associated with reduced ischemic events including stent thrombosis, myocardial infarction and stroke following PCI. However, the tradeoff is an increased risk for bleeding while on DAPT. The addition of a novel oral anticoagulant (NOAC) further increases the likelihood of bleeding while on antiplatelet therapy. Thus, the overall risks and benefits for each patient undergoing PCI on NOAC must be assessed and therapy individualized to ensure optimal therapy for each unique situation. Patients on NOAC undergoing PCI should undergo routine assessment with intravascular imaging as the role of high-risk lesion-related features have increased importance prior to determining optimal duration of treatment with DAPT. We review the best practices for the pharmacologic management of patients requiring anticoagulation with NOAC who are treated with PCI and require antiplatelet therapy.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element IN PROCESS -- NOT YET INDEXED
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Heart & Vascular Institute
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
657 ## - INDEX TERM--FUNCTION
Medline publication type Review
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Shlofmitz, Evan
790 ## - Authors
All authors Lee MS, Shlofmitz E, Shlofmitz R
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.4070/kcj.2019.0185">https://dx.doi.org/10.4070/kcj.2019.0185</a>
Public note https://dx.doi.org/10.4070/kcj.2019.0185
858 ## - ORCID
ORCID text Shlofmitz, Evan
Orcid <a href="https://orcid.org/0000-0002-0907-5258">https://orcid.org/0000-0002-0907-5258</a>
Name https://orcid.org/0000-0002-0907-5258
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 08/23/2019   31347321 31347321 08/23/2019 08/23/2019 Journal Article

Powered by Koha